Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655304> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4385655304 endingPage "e8815033" @default.
- W4385655304 startingPage "e8815033" @default.
- W4385655304 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: Myeloproliferative neoplasms (MPN) describe a group of diseases characterized by increased proliferation of the myeloid series in the bone marrow. MPNs are classified into four different subgroups: 1) Chronic Myeloid Leukemia (CML), 2) Philedelphia chromosome-negative classical MPNs such as Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF), 3) Non-classical Philadelphia chromosome-negative MPNs (Chronic Neutrophilic Leukemia, CNL; Chronic Eosinophilic Leukemia, CEL) and 4) Unclassifiable-MPN (MPN-u). Aims: In our study, we aimed to reveal the possible effect of hydroxyurea on inflammation as the cytoreductive treatment of BCR-ABL negative MPNs. Methods: In this study, BCR-ABL negative MPNs were grouped as PV, ET, PMF and others. Subtype of diagnosis, age, gender, genetic mutations at the time of diagnosis, treatment and follow-up preferences, laboratory results (leukocyte, neutrophil, thrombocyte, C - reactive protein (CRP) and lactate dehydrogenase (LDH)) at 0.-3.-6. and 12.months were recorded. Alterations in inflammatory indicators such as leukocytes, neutrophils, CRP, LDH, neutrophil- lymphocyte ratio (NLR) and systemic immune inflammatory index (SIII) were examined in patients who treated with hydroxyurea. Results: A total of 298 patients; 121 females (%40.6) and 177 males (%59.4) were included in our study. While 70 patients were in MPN-u group (%23.49), 97 patients in PV (%32.55), 105 patients in ET (%35.23) and 26 patients were in PMF group (%8.72). Fifty-three percent of total and 92 percent of patients with cytoreductive therapy were receiving hydroxyurea. There was a considerable decrease neutrophil and leukocyte values between 0.-3.,0.-6. and 0.-12. months in patients receiving hydroxyurea (p<0.001). Also in the same group, significant decrease in NLR was detected between 0.-3. and 0.-6. months (p=0.001 and p=0.01). In terms of the systemic immune inflammatory index, a significant decrease was found between 0.-3., 0.-6. and 0.-12. months (p<0.001). Summary/Conclusion: In this study, we found a statistically significant decrease in neutrophil, leukocyte, NLR and SIII values in the group receiving hydroxyurea. The decrease in SIII which includes neutrophil and platelet values was more remarkable. We think that the study should be evaluated together with cytokines in a larger patient group in order to mention the effect of hydroxyurea on inflammation more clearly.Keywords: Myeloproliferative disorder, Hydroxyurea, Inflammation" @default.
- W4385655304 created "2023-08-09" @default.
- W4385655304 creator A5036058104 @default.
- W4385655304 creator A5054467773 @default.
- W4385655304 creator A5090573083 @default.
- W4385655304 date "2023-08-01" @default.
- W4385655304 modified "2023-09-27" @default.
- W4385655304 title "PB2234: EFFECT OF HYDROXYUREA ON INFLAMMATORY MARKERS IN PATIENTS WITH BCR-ABL NEGATIVE MYELOPROLIFERATIVE DISEASES" @default.
- W4385655304 doi "https://doi.org/10.1097/01.hs9.0000975676.88150.33" @default.
- W4385655304 hasPublicationYear "2023" @default.
- W4385655304 type Work @default.
- W4385655304 citedByCount "0" @default.
- W4385655304 crossrefType "journal-article" @default.
- W4385655304 hasAuthorship W4385655304A5036058104 @default.
- W4385655304 hasAuthorship W4385655304A5054467773 @default.
- W4385655304 hasAuthorship W4385655304A5090573083 @default.
- W4385655304 hasBestOaLocation W43856553041 @default.
- W4385655304 hasConcept C104317684 @default.
- W4385655304 hasConcept C126322002 @default.
- W4385655304 hasConcept C138626823 @default.
- W4385655304 hasConcept C203014093 @default.
- W4385655304 hasConcept C2778729363 @default.
- W4385655304 hasConcept C2778837598 @default.
- W4385655304 hasConcept C2778904597 @default.
- W4385655304 hasConcept C2779282312 @default.
- W4385655304 hasConcept C2780007613 @default.
- W4385655304 hasConcept C2780076729 @default.
- W4385655304 hasConcept C2781057849 @default.
- W4385655304 hasConcept C2781107747 @default.
- W4385655304 hasConcept C2910274570 @default.
- W4385655304 hasConcept C55493867 @default.
- W4385655304 hasConcept C71924100 @default.
- W4385655304 hasConcept C86803240 @default.
- W4385655304 hasConcept C90924648 @default.
- W4385655304 hasConceptScore W4385655304C104317684 @default.
- W4385655304 hasConceptScore W4385655304C126322002 @default.
- W4385655304 hasConceptScore W4385655304C138626823 @default.
- W4385655304 hasConceptScore W4385655304C203014093 @default.
- W4385655304 hasConceptScore W4385655304C2778729363 @default.
- W4385655304 hasConceptScore W4385655304C2778837598 @default.
- W4385655304 hasConceptScore W4385655304C2778904597 @default.
- W4385655304 hasConceptScore W4385655304C2779282312 @default.
- W4385655304 hasConceptScore W4385655304C2780007613 @default.
- W4385655304 hasConceptScore W4385655304C2780076729 @default.
- W4385655304 hasConceptScore W4385655304C2781057849 @default.
- W4385655304 hasConceptScore W4385655304C2781107747 @default.
- W4385655304 hasConceptScore W4385655304C2910274570 @default.
- W4385655304 hasConceptScore W4385655304C55493867 @default.
- W4385655304 hasConceptScore W4385655304C71924100 @default.
- W4385655304 hasConceptScore W4385655304C86803240 @default.
- W4385655304 hasConceptScore W4385655304C90924648 @default.
- W4385655304 hasIssue "S3" @default.
- W4385655304 hasLocation W43856553041 @default.
- W4385655304 hasLocation W43856553042 @default.
- W4385655304 hasOpenAccess W4385655304 @default.
- W4385655304 hasPrimaryLocation W43856553041 @default.
- W4385655304 hasRelatedWork W1858042755 @default.
- W4385655304 hasRelatedWork W2011378064 @default.
- W4385655304 hasRelatedWork W2037936911 @default.
- W4385655304 hasRelatedWork W204834199 @default.
- W4385655304 hasRelatedWork W2128623293 @default.
- W4385655304 hasRelatedWork W2134237116 @default.
- W4385655304 hasRelatedWork W2182419105 @default.
- W4385655304 hasRelatedWork W2294849349 @default.
- W4385655304 hasRelatedWork W3207834645 @default.
- W4385655304 hasRelatedWork W4210486064 @default.
- W4385655304 hasVolume "7" @default.
- W4385655304 isParatext "false" @default.
- W4385655304 isRetracted "false" @default.
- W4385655304 workType "article" @default.